<?xml version="1.0" encoding="UTF-8"?>
<p>Targeting CDKs is one of the promising strategies in cancer chemotherapy
 <xref rid="CIT0006" ref-type="bibr">
  <sup>6</sup>
 </xref>. The success of this strategy was confirmed by many CDK inhibitors which reached phase I/II clinical trials as potential anticancer agents
 <xref rid="CIT0014" ref-type="bibr">
  <sup>14</sup>
 </xref>. Previously, several compounds with pyrrolizine-5-carboxamide scaffold exhibited weak to moderate inhibitory activity against CDK-2
 <sup>24,</sup>
 <xref rid="CIT0025" ref-type="bibr">
  <sup>25</sup>
 </xref>.
</p>
